SynthesisInternal medicine (Tokyo, Japan)2026
Two-year Follow-up of IgA Nephropathy Patients Who Developed Gross Hematuria Following COVID-19 Vaccination: A Case Series and Literature Review.
Synthesis in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective Recent reports have shown that patients with immunoglobulin A nephropathy (IgAN) develop gross hematuria after COVID-19 vaccination. However, the two-year prognosis remains uncertain. Methods We conducted a retrospective review of 301 patients with IgAN at our institution to identify those who developed gross hematuria after COVID-19 vaccination. We evaluated the patients' baseline characteristics, clinical courses, and changes in the renal function, proteinuria, and hematuria for two years post-vaccination. In addition, we conducted a systematic literature review of 16 case studies, with 28 cases and 5 cohort studies. Results Gross hematuria was observed in eight patients after vaccination. Their mean age was 42.9 years, and 87.5% were women. All patients relapsed or did not achieve clinical remission prior to vaccination. The median time to gross hematuria onset was 1.6 days, resolving within 3 days. The mean baseline estimated glomerular filtration rate (eGFR) was 69.4 mL/min/1.73 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.